Forbes January 17, 2021
The Trump Administration’s grandiose healthcare plans didn’t come to fruition, like the promised repeal and replace of the Affordable Care Act, the pledged overhaul of the prescription drug rebate system, and international price indexing for Medicare Part B (physician-administered) drugs. Yet, Secretary Azar’s Department of Health and Human Services (HHS) and Administrator Verma’s Centers for Medicare and Medicaid Services (CMS) have implemented a number of high-profile regulations that will likely have a lasting impact on the pricing and reimbursement of medical services and technologies.
For well over a decade, policymakers have declared the healthcare system is moving towards value-based pricing of medical services and technologies. Nonetheless, the movement from volume- to a value-based system of pricing has occurred at a...
Today's Sponsors
Today's Sponsor